[D-Ala2, Met5]-Enkephalinamide

<strong>[D-Ala2,Met5]-Enkephalinamide</strong> <strong>Catalog number:</strong> MDP0491 <strong>CAS Number: </strong>103412-42-6 <strong>Sequence: </strong>Tyr-D-Ala-Gly-Phe-Met-NH2 <strong>Amount:</strong> 500 ug <strong>Molecular Weight:</strong> 586.4 g/mol <strong>Supplied as:</strong> Powder <strong>Applications:</strong> molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>WARNING:</strong> For in vitro Research Use Only. NOT for use on humans or animals. <strong>Grade:</strong> Biotechnology grade. All products are highly pure. <strong>References:</strong> 1: Wong-Dusting HK, Rand MJ. Effect of [D-Ala2,Met5]enkephalinamide and [D-Ala2,D-Leu5]enkephalin on cholinergic and noradrenergic neurotransmission in isolated atria Eur J Pharmacol. 1985 Apr 23;111(1):65-72. 2: Audigier Y, Mazarguil H, Roy J, Morgat JL, Cros J. Binding and metabolism studies with [3H](D-Ala2,Leu5)enkephalinamide and [3H](D-Ala2,Pro5)enkephalinamide: evidence for a selective interaction of (D-Ala2,Pro5)enkephalinamide with mu-receptors Eur J Pharmacol. 1981 Sep 24;74(4):273-8. 3: Quito FL, Brown DR. [D-Ala2, Met5]-enkephalinamide: CNS-mediated inhibition of prostaglandin-stimulated intestinal fluid and ion transport in the rat Peptides. 1987 Nov-Dec;8(6):1029-33. 4: Wong TM, Chan SH, Tse SY. Central cardiovascular actions of D-Ala2-Met5-enkephalinamide in the rat: effects of naloxone and nucleus reticularis gigantocellularis lesion Neurosci Lett. 1984 May 18;46(3):249-54. 5: Zacharko RM, Maddeaux C, Hebb AL, Mendella PD, Marsh NJ. Vulnerability to stressor-induced disturbances in self-stimulation from the dorsal and ventral A10 area: differential effects of intraventricular D-Ala2-Met5-enkephalinamide, D-Ala2, N-Me-Phe4, Gly-Ol5-enkephalin, and D-Pen2, D-Pen5-enkephalin administration Brain Res Bull. 1998 Oct;47(3):237-48. 6: Sandi C, Borrell J, Guaza C. D-Ala2-Met5-enkephalinamide impairs the acquisition of ethanol preference without influencing sucrose preference Physiol Behav. 1990 Sep;48(3):435-9. 7: Phillips AG, LePiane FG. Reward produced by microinjection of (D-Ala2),Met5-enkephalinamide into the ventral tegmental area Behav Brain Res. 1982 Jun;5(2):225-9. 8: Hebb AL, Zacharko RM. Central D-Ala2-Met5-enkephalinamide mu/delta-opioid receptor activation reverses the anxiogenic-like properties of cholecystokinin on locomotor and rearing activity in CD-1 mice Brain Res. 2003 Apr 25;970(1-2):9-19. 9: Jefferys D, Copolov D, Funder JW. Naloxone inhibits both glucocorticoid and [D-Ala2,Met5]enkephalinamide reversal of behavioural effect of adrenalectomy Eur J Pharmacol. 1984 Aug 17;103(3-4):205-10. <a href="https://pubmed.ncbi.nlm.nih.gov/3208116">10: Brutus M, Zuabi S, Siegel A. Effects of D-Ala2-Met5-enkephalinamide microinjections placed into the bed nucleus of the stria terminalis upon affective defense behavior in the cat Brain Res. 1988 Nov 8;473(1):147-52. </a> <br><strong>Products Related to [D-Ala2,Met5]-Enkephalinamide can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>